NASDAQ:RGLS Regulus Therapeutics (RGLS) Stock Price, News & Analysis $1.80 +0.04 (+2.27%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$1.71▼$1.8250-Day Range$1.76▼$2.6952-Week Range$1.08▼$3.79Volume374,195 shsAverage Volume1.68 million shsMarket Capitalization$117.85 millionP/E RatioN/ADividend YieldN/APrice Target$11.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Regulus Therapeutics alerts: Email Address Regulus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside552.8% Upside$11.75 Price TargetShort InterestBearish6.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.59) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.92 out of 5 starsMedical Sector799th out of 896 stocksPharmaceutical Preparations Industry375th out of 424 stocks 3.4 Analyst's Opinion Consensus RatingRegulus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRegulus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Regulus Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.77% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Regulus Therapeutics has recently increased by 38.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RGLS. Previous Next 2.1 News and Social Media Coverage News SentimentRegulus Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Regulus Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for RGLS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.35% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regulus Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regulus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] “This Could Be Worth 28X More than NVIDIA”This firm's stock is currently trading for only $15. But that won't last long. Because even OpenAI founder Sam Altman admits AI "depends" on this firm's work.Click here for the ticker >>> About Regulus Therapeutics Stock (NASDAQ:RGLS)Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More RGLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGLS Stock News HeadlinesJune 29, 2024 | americanbankingnews.comBrokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Target Price at $11.75June 26, 2024 | americanbankingnews.comAnalysts Offer Predictions for Regulus Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:RGLS)July 5, 2024 | Behind the Markets (Ad)Historic NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's next?June 26, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Price Target Raised to $28.00 at Canaccord Genuity GroupJune 25, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Price Target Raised to $10.00June 24, 2024 | prnewswire.comRegulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)June 4, 2024 | prnewswire.comRegulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesMay 16, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerJuly 5, 2024 | Behind the Markets (Ad)Historic NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's next?May 16, 2024 | prnewswire.comRegulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerMay 13, 2024 | theguardian.comStarwatch: the moon celebrates with a cruise past RegulusMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429May 10, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 9, 2024 | msn.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024May 9, 2024 | prnewswire.comRegulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus’s Innovative ADPKD Therapy RGLS8429May 6, 2024 | prnewswire.comRegulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)April 30, 2024 | prnewswire.comRegulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesApril 10, 2024 | seekingalpha.comRegulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKDMarch 28, 2024 | markets.businessinsider.comBuy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment NeedsMarch 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development MilestonesMarch 23, 2024 | finance.yahoo.comRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical AdvancementsMarch 22, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 21, 2024 | investorplace.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023March 21, 2024 | finance.yahoo.comRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment DataMarch 15, 2024 | finance.yahoo.comRGLS Mar 2024 7.500 putSee More Headlines Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/04/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RGLS CUSIP75915K10 CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$11.75 High Stock Price Target$28.00 Low Stock Price Target$3.00 Potential Upside/Downside+552.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.69% Return on Assets-55.45% Debt Debt-to-Equity RatioN/A Current Ratio17.85 Quick Ratio17.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book1.71Miscellaneous Outstanding Shares65,470,000Free Float62,618,000Market Cap$117.85 million OptionableOptionable Beta1.62 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Joseph P. Hagan M.B.A. (Age 55)CEO & Director Comp: $958.23kMs. Crispina Calsada CPA (Age 54)Chief Financial Officer Comp: $579.3kMr. Christopher Ray Aker J.D. (Age 63)Senior VP, General Counsel & Corporate Secretary Comp: $575.94kDr. Preston S. Klassen M.D. (Age 55)M.H.S., President, Head of Research & Development and Director Mr. Daniel J. Penksa (Age 38)VP of Finance & Controller Dr. Claire Susan Padgett M.S.M.T., Ph.D., Senior Vice President of Clinical OperationsDr. Rekha Garg M.D.M.S., Senior Vice President of Clinical Development & RegulatoryMr. Edmund Lee Ph.D.Vice President of Translational MedicineMore ExecutivesKey CompetitorsAlimera SciencesNASDAQ:ALIMLexicon PharmaceuticalsNASDAQ:LXRXEmergent BioSolutionsNYSE:EBSVanda PharmaceuticalsNASDAQ:VNDAAgenusNASDAQ:AGENView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Bought 170,308 shares on 5/29/2024Ownership: 0.260%RA Capital Management L.P.Bought 6,250,000 shares on 5/17/2024Ownership: 9.547%NEA Management Company LLCBought 6,467,802 shares on 5/15/2024Ownership: 9.879%Vanguard Group Inc.Bought 453,784 shares on 5/10/2024Ownership: 1.131%CVI Holdings LLCBought 1,406,250 shares on 5/7/2024Ownership: 2.148%View All Insider TransactionsView All Institutional Transactions RGLS Stock Analysis - Frequently Asked Questions Should I buy or sell Regulus Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGLS shares. View RGLS analyst ratings or view top-rated stocks. What is Regulus Therapeutics' stock price target for 2024? 5 brokers have issued 1-year price targets for Regulus Therapeutics' stock. Their RGLS share price targets range from $3.00 to $28.00. On average, they anticipate the company's stock price to reach $11.75 in the next year. This suggests a possible upside of 552.8% from the stock's current price. View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts. How have RGLS shares performed in 2024? Regulus Therapeutics' stock was trading at $1.28 at the start of the year. Since then, RGLS shares have increased by 40.6% and is now trading at $1.80. View the best growth stocks for 2024 here. Are investors shorting Regulus Therapeutics? Regulus Therapeutics saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 3,580,000 shares, an increase of 38.2% from the May 31st total of 2,590,000 shares. Based on an average daily trading volume, of 703,100 shares, the short-interest ratio is presently 5.1 days. Approximately 6.8% of the shares of the company are short sold. View Regulus Therapeutics' Short Interest. When is Regulus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our RGLS earnings forecast. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.14. When did Regulus Therapeutics' stock split? Shares of Regulus Therapeutics reverse split before market open on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO? 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN). How do I buy shares of Regulus Therapeutics? Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RGLS) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredUrgent: Safeguard Your Finances from Biden NOWHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.